Routine succession planning for a non-CEO/CFO role with an internal successor already in place. No trading implications; monitor the 10-K filing in February 2027 for any related financial disclosures.
TVTX drugs
TVTX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 10 $56.59entry
- T+1 · 4mo ago −0.53%α +0.24% · $56.29
- T+5 · 4mo ago −2.31%α −1.75% · $55.28
- T+20 · 3mo ago +8.36%α +5.93% · $61.32
- T+60 · 6w ago +1.91%α −0.72% · $57.67
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Travere Therapeutics announced the planned retirement of CAO Sandra Calvin after the filing of the 2026 10-K (expected February 2027), with VP Controller John Torell set to succeed her. The transition is orderly with an internal replacement already named, making this a routine personnel event with no material financial impact.
Key Facts
- CAO Sandra Calvin intends to retire following the filing of the 2026 annual report (expected February 2027).
- John Torell, CFA, CPA, currently VP Controller, is expected to succeed her as CAO and PAO.
- Torell joined Travere in 2021 and has overseen accounting operations, financial reporting, SEC reporting, and internal controls.
- The Board is expected to appoint Torell in advance of the Retirement Date to ensure an orderly transition.
Financial Impact
No financial impact from this executive transition.
Risk Factors
- Potential disruption if the transition timeline shifts or if Torell declines the appointment, though the filing indicates a clear plan.
- No other risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001438533-26-000054 |
| Document: 0001438533-26-000054-index-headers.html | 0001438533-26-000054 |
| Document: 0001438533-26-000054-index.html | 0001438533-26-000054 |
| Document: 0001438533-26-000054.txt | 0001438533-26-000054 |
Track record
21 reports on TVTX
8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +56.24% at T+60 after the Jun 2, 2026 report. 10 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $50.30 Now $49.70 −1.19% settles Nov 23
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $48.87 to $51.56 Now $49.70 +1.70% ▲ +5.50% +2.21% vs SPY
- Nov 3, 202613d ago Institutional Cluster Bullish 4/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Sep 17, 20268w ago Insider Cluster Bearish 4/10 Entry $62.76 to $59.44 Now $49.70 +20.81% ▲ +5.29% +6.56% vs SPY
- Jul 9, 202618w ago 8-K Neutral 2/10 Viewing Entry $56.59 to $55.28 Now $49.70 −12.18% ▼ −2.31% −1.75% vs SPY
- Jun 16, 202621w ago Insider Cluster Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 16, 202621w ago 8-K Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 12, 202622w ago 144 Neutral 2/10 Entry $52.04 to $55.15 Now $49.70 −4.50% ▲ +5.98% +5.30% vs SPY
- Jun 2, 202623w ago 8-K Bullish 6/10 Entry $42.96 to $48.57 Now $49.70 +15.69% ▲ +13.06% +16.02% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers